Volixibat 新

参考资料仅供科学研究，不可用于个人用途。

货号：BCP24905CAS号：1025216-57-2纯度：98%

在线咨询

购买咨询

全国免运费！免费咨询：400-099-8200 或手机联系：13472751340

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS号	1025216-57-2	货号	BCP24905
中文名	Volixibat
英文名	Volixibat
中文别名
英文别名	LUM-002; LUM 002; LUM002; SHP-626; SHP 626; SHP626; SAR-548304; SAR548304; SAR 548304;
SMILES	CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)C(C1O)C3=CC(=CC=C3)NC(=O)NC4C(C(C(C(O4)COS(=O)(=O)O)O)OCC5=CC=CC=C5)O)CC
化学名称
分子式	C38H51N3O12S2	分子量	805.96
纯度	98%	配送	惯例下常温包邮
产品描述	Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). If approved for use, it will be the first available agent for the treatment of NASH. Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum. Also known as the ileal bile acid transporter (IBAT), ASBT is primarily responsible for the enterohepatic recirculation of bile acids and ultimately for hepatic lipid and glucose metabolism. Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for the treatment of NASH as abnormal cholesterol metabolism and accumulation of free cholesterol in the liver have been implicated in its pathogenesis. According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments for NASH.